I have diverse leadership experience as a health services professional with significant accomplishments in all aspects of pharmacovigilance, clinical development, medical affairs, regulatory affairs, primary health care, project management & international health programs. I have vast experience of working in diverse therapeutic areas including rare diseases, novel preventive & therapeutic vaccines, monoclonal antibodies, cardiovascular, oncology, neurology, nosocomial diseases, generic and OTC medicines. I am currently working as Disease Area Cluster Lead for Biosimilars & Drug Delivery Devices at Pfizer. Currently Pfizer has the largest biosimilars portfolio in the industry that includes projects on Inflammation, Oncology, Hematology, ophthalmology etc. My past experience includes working as Associate vice president PV and Therapeutic Area Head (Rare Diseases) for Sanofi Genzyme, working as Senior Director & Director for vaccines PV at Sanofi Pasteur, working as Medical Consultant for Apotex Inc Canada. Prior to joining industry I had worked as Joint Executive Director for Pakistan Institute of Medical Sciences (PIMS), Registrar of the Post graduate medical institute PIMS and as Deputy Director General, Ministry of Health Pakistan. I have also worked on various primary healthcare, public health, health planning & development programs as well World food, UNICEF, WHO & JICA assisted programs on drug safety, emergency preparedness, and primary healthcare.

Pharmacovigilance, Drug safety

Swamy K B has been awarded with PhD by Andhra University, his Master’s Degree MS (in Clinical Anatomy) from Andhra Medical College, D M C h (Maternal & Child Health) from IGNOU, New Delhi, his Medical Degree (MBBS) in 1976, from SV University, India. He has expertise in multi medical disciplines, Human Genetics, Reproductive Health & Developmental Anatomy and in Herbal Medicine. He has been the genetic counsellor for many Medical institutions. He possess prestigious grants FRGS,URGS from Malaysia, he has conducted researches on Herbal Medicine and Diabetes, “Brain size and Intelligence Quotient (IQ)”, He has been the former founder Anatomist, Professor and Head for many Medical Schools in India as well as in Malaysia. He is an International Editorial Board Member for many reputed journals like Anatomical Society of India (ASI). Recently he has been unanimously elected as an Executive Board Member for ASI and an Organizing Committee Member for the upcoming 8th World Congress on Toxicology at Dubai, UAE “9th Euro-Global Summit to be held at Paris and 11th International Congress on Toxicology and Risk Management to be held at October 10-12, 2017 in London, UK.

Human Genetics, Reproductive Health & Developmental Anatomy and in Herbal Medicine.

After completion of his postdoctoral training at University of Texas MD Anderson Cancer Center, Dr. Gautam Sethi joined Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore in 2008 as an Assistant Professor and was promoted to Associate Professor in 2015. The focus of his research over the past few years has been to elucidate the mechanism (s) of activation of oncogenic transcription factors such as NF-kB/STAT3 by carcinogens and inflammatory agents and the identification of novel inhibitors of these proteins for prevention of and therapy for cancer. His group has identified numerous small molecules from natural sources that can suppress various pro-tumorigenic signaling cascades involved in cancer initiation and promotion. The findings of his research work have so far resulted in more than one fifty scientific publications in high impact factor peer reviewed journals and several international awards. He currently serves as an Academic Editor for prestigious PLOS One journal and on the editorial board member of several journals including Scientific Reports and Frontiers in Pharmacology

Pharmacology, Pharmacovigilance,Drug Safety

He is a chair of St. Anne's University Hospital

Advance knowledge, improve clinical care and promote advocacy to power better quality of life of patients with dementia

Shibo Jiang received postdoctoral training at Rockefeller University (1987-1990) and worked as Member and Lab Head at the New York Blood Center (1990-2010), and as a professor (Thousands-talent scholar) at Fudan University (2010-). He has focused on development of antiviral therapeutics and vaccines. He discovered the first highly potent anti-HIV peptide and his patent was licensed to Trimeries Pharmaceutical for developing the first US FDA-approved peptide HIV entry inhibitor - Fuzeon (enfuvirtide or T20). He developed the first anti-HPV therapeutic - JB01 protein. He has published 360 SCI papers in high profile journals (e.g., Nature, Nature Medicine, Nature Communication, Nature Review Microbiology, Lancet, Cell, PNAS etc) with total impact factors of 1,686 and >10,000 citations. He has obtained 18 US and 5 Chinese patents, 8 US NIH grants (>20 millions USD) and 8 Chinese grants (>20 millions RMB), and given more than 180 oral presentations in more than 30 countries

Drug Safety, Pharmacovigilance,HPV

Dr. Yusuf TUTAR is the Head of Biochemistry Division and the Head of Basic Sciences Department at Faculty of Pharmacy, Cumhuriyet University, Sivas Turkey. Dr. Tutar is also the Head of Biomedical Engineering Program at the same university. He obtained his M.Sc. and Ph.D. at Oregon State University and Texas Tech University respectively. He pursued his postdoctoral study at National Institutes of Health (NIH/NIDDK), USA

His research focuses on Biochemistry, Biophysics, Genetics, and Molecular Biology with specialization in the fields of protein structure-function, protein folding, prion, microrna, pseudogenes, molecular cancer, proteomics, genomics, protein expression and characterization by spectroscopic and calorimetric methods.

Dr. Nagwa Ali Sabri is a Professor of Clinical Pharmacy and Head of Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University, Egypt. She has a Diploma in Medical Informatics from SIRA Institute, USA., IRCA Certified Lead Auditor ISO 9001:2015 and Certified Pharmacovigilance Specialist (Qualified Person for Pharmacovigilance (QPPV). She is a Principal Investigator and member of institutional review board of Drug Research Centre (Bioequivalence Centre, Cairo-Egypt). Member in Biocides Technical Committee of Ministry of Health. Dr. Nagwa’s areas of interest include; teaching, supervising different activities of under and post-graduate students, investment of clinical pharmacy activities in community pharmacies and hospitals, undergoing Bioequivalence and Bio-waiver studies according to international guidelines and Pharmacovigilance. She has more than 25 years of academic experience, and more than 19 years of experience in bioequivalence and advanced pharmaceutical research, principal investigator in about 300 Bioequivalence studies, Bio-waiver studies, expert reports and others. She owns a significant experience in establishment of quality assurance system and advanced training schedule in Bioequivalence and Pharmacovigilance field. She has more than 45 published researches and more than 30 national and international awards and prizes.

Clinical Pharmacy Practice and Pharmacotherapy. -Bioequivalence, Pharmacokinetics and Clinical Pharmacokinetics. -Pharmacovigilance. - Clinical Trials. -Pharmaceutics, drug formulation, in vitro testing (dissolution, disintegration, weight variation,…etc). -Analytical Method development and its application (HPLC and LC/MS/MS). - Quality Assurance Systems, Certification and Accreditaion.

Samar N. El-Beshbishi has completed here PhD-research and postdoctoral studies from University of Texas Medical Branch, Galveston, Texas-USA. She is professor of Medical Parasitology, Faculty of Medicine, Mansoura University, Egypt. She has her expertise in schistosomal therapeutic and immunological studies. She has published more than 30 papers in reputed journals and has been serving as an editorial board member and reviewer of repute.

Pharmacovigilance, Parasitology

Presently working as a Principal Scientist in the Department of Pulmonary Medicine and Sleep Disorders, AIIMS, New Delhi. Diligent & competent professional with a trailblazing 12 years of committed clinical health research experience. Post Doctoral Fellowship in Clinical Health (Genetics of obesity, fatty liver and sleep medicine), from Department of PMSD, AIIMS, New Delhi, India PhD in clinical health (Biotechnology) from AIIMS, Institute of Genomics & Integrative Biology (IGIB) and Jamia Hamdard University, New Delhi, India. Academically proficient with Master in Business Administration (MBA) in Human Resource (HR) from Guru Jameshawar University Haryana and Master in Science (M.Sc) in Biomedical Science and Post Graduate Diploma In Biomedical Technology from Garhwal University, Uttarakhand.

Genetics of obesity, diabetes, fatty liver, obstructive sleep apnea, cardiovascular disease and vitamin D deficiency

Presently working as an Assistant Professor of Clinical Pharmacy in the Department of Clinical Pharmacy, Faculty of Pharmacy, Guilan University of Medical Sciences. Graduated with Pharm.D degree from School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran in 2011. After graduation, she began the academic study program for degree of specialty in pharmacotherapy in Tehran University of Medical Sciences, Tehran, Iran and obtained her certificate in clinical pharmacy specialty.

Pharmacotherapy, Pharmacovigilance, Drug utilization evaluation, Clinical trials, Drug-induced Nephrotoxicity

Khaudeja is a Physician with a Masters in Clinical Research (UCSD), Pharmaceutical engineering Certification, an Oracle DBA, and a certified Project Management Professional. She is an Abbott President’s award winner, avid Toastmaster and certified coach. Khaudeja has more than 25 years professional experience, including clinical practice. She has held several global safety positions at Abbott Vascular, Abbott Diagnostics, Abbott Established Pharma Division and now AbbVie Inc. Her career in safety includes global leadership roles in devices, diagnostics, pharmaceuticals and combination products.

Pharmacovigilance, Drug Safety

Akwete (Lex) Adjei, PhD has a wealth of experience in drug design and drug delivery technology. After receiving his PhD from the University of Texas, Austin, Lex did his postgraduate work on complexation of xanthine drugs in non-ideal sovent systems. Lex has held positions at several pharmaceutical companies and currently is Executive Director of R&D at Rhodes Pharmaceuticals, L.P. He has been the author/co-author of 38 published peer-reviewed articles and 15 books or book chapters and he has almost 50 patents for his work in this area. He is an experienced presenter with more than 25 presentations by special invite.

Pharmacovigilance, Pharmacology, Pharmaceuticals

Massoud Toussi, MD, PhD, MBA, is leader of Pharmacoepidemiology and Drug Safety Activities in IMS Health. Massoud is medical doctor with an MD degree in general medicine and a university degree in psychiatry. After working as a clinician for about three years he specialized himself in in medical informatics and pharmacoepidemiology and the analysis of healthcare data by obtaining a Master’s degree and a PhD in this domain. He also obtained an MBA from University of Paris Dauphine (France) and a Master’s degree international management from Unviersity of Quebec-Montreal (Canada). He is an active member of the International Society of harmacoepidemiology (ISPE), European Network of centers of Pharmacoepidemiology and Pharmacovigilance (ENCePP) and European Public Health Association (EUPHA).

Pharmacovigilance, Pharmacology

Ehab Founded TopLab co. For IVF (In vitro fertilization) labs consultations in 2014. It did many researchs in ART (Assisted reproductive techniques). He got his masters degree in Health care management in 2013, after his postgraduate studies from university of Bristol, United Kingdom in 2009. He is a medical school graduate, Ain shams Univ., Egypt. Ehab is running many IVF labs in Egypt and UAE. His consultations company is running national and international training courses for ART techniques. His years of expereinces gave him the ability to set up labs., and improve others performances through his company’s services.

In vitro fertilization, Assisted reproductive techniques,

Hayam Ateyya has completed her MB.Bch degree in medicine& surgery at the age of 25 years from Cairo University, Faculty of Medicine and M.D Degree in Pharmacology from Cairo University, faculty of Medicine. She is working now as assistant professor at Taibah university in KSA.

Pharmacovigilance, Pharmacology.

Dr. Mohamed A. Morsy has completed his BS & MS at Alexandria University, Alexandria, Egypt (1987) and PhD from King Fahd University of Petroleum & Minerals College of Sciences, Dhahran, Saudi Arabiaty (1993). He has published more than 40 papers in reputed journals on many EPR invistigations including Liquid Crystals, Drugs Analysis, Tea and Tobacco Leaves Quality, etc. Currently, he is interested in the mechanistic chemistry of chemical, photo, and electrochemical oxidation using different spectroscopic techniques. He is often using free radicals and EPR to characterize the reactivity of nanomaterials and free radicals in other systems.

Drug analysis,Drug formulation, Pharmacovigilance

Dr. Elnour has received his PhD in School of Pharmacy, Queen’s University Belfast, N. Ireland-United Kingdom during the period of 2000-2004. Currently, he is working as Adjunct Clinical Associate Professor in Pharmacology Department at United Arab Emirates University. He is serving as an editorial member of several reputed journals like Journal of Medicine, Institute of Research Engineers and doctors, Journal of Pharmacy Research, International Journal of Biomedical Sciences and Bioinformatics, Symbiosis Journal of Pharmacy and Pharmaceutical Sciences, Pharmacology and Pharmacy, International Journal of Medical Sciences and Biotechnology. He has authored 31research articles, Meta-analysis and Editorial Letters. He is a member of several professional and therapeutics committees like Clinical pharmacy Council, Al Ain hospital representative, SEHA, Abu Dhabi and chairperson for Team Leader of Pharmacy and Therapeutic Committee (PTC) – Drug Utilization Evaluation Subcommittee (DUES).

The Role of Clinical Pharmacist in Pharmacovigilance,Pharmacovigilance,Pharmacology

Dr.Farhan Ahmad Khan was In charge of, Drugs & Therapeutic Committee, TM Medical College & Research Centre and was involved in various activities such as, Running Drug Information Centre, Adverse Drug Reporting, Protocol designing for Clinical Trials, Teaching and training of Undergraduate Medical Students, Training and supervision of Postgraduate students in Pharmacology, Helping Physicians in Treatment Guidelines, also was Incharge of Sports Club University, Designing, and writing clinical protocols. The other responsibilities in which Dr Farhan was involved are Training and supervision of Postgraduate students (MD, MSc) in Pharmacology,Designing Syllabus & Curriculum of Postgraduate students (MD, MSc) &Undergraduate students, was in charge of Drugs Recommendation & Evaluation Committee & Pharmacovigillance Committee.

Pharmacovigilance, Clinical Pharmacology, Immunopharmacology, Therapeutic Drug Monitoring, Rational Use of Drugs, Clinical Trial

Mario Bertazzoli is a physician and a registered specialist in Human Reproduction Pathology. He received both medical and specialization degrees from the University of Milan, Italy. He worked since 1995 for international pharmaceutical companies as pharmacovigilance and pharmaco-epidemiology physician. He is currently the Head of Corporate Drug Safety and Reference Physician to the EU Qualified Person for Pharmacovigilance for the Helsinn Group. He is founder and treasurer of the International Society of Pharmacovigilance, Swiss-Austrian Chapter.

Worldwide Pharmacovigilance (especially US, EU, Switzerland, China and Japan), Benefit-risk management and Pharmacoepidemiology.

Microbiology, Genetics, Immunology, Virology, Immunopharmacology, Cell Biology

Microbiology, Genetics, Immunology, Virology, Immunopharmacology, Cell Biology,

Saad Shakir qualified in Medicine in 1976 and worked in hospital medicine for eleven years before moving to general practice. He has been working in pharmacovigilance & pharmacoepidemiology for more than a decade, initially at the Medicines Control Agency (MCA) in the UK then in the international pharmaceutical industry.He was appointed as the Director of the Drug Safety Research Unit (DSRU) in Southampton in 1999. The DSRU is an academic Unit associated with the University of Portsmouth. At the DSRU he leads a research team with an active programme for monitoring and studying the safety of medicines. Saad Shakir is a Fellow of the Royal Colleges of Physicians in Glasgow, Edinburgh and London, a Fellow of the Faculty of Pharmaceutical Medicine, a Fellow of the International Society of Pharmacoepidemiology and a Member of the Royal College of General Practitioners in the UK. He continues to practice clinical medicine part-time. He has worked and advised on many drug safety issues including product withdrawals and major safety hazards. He is an author of many publications in scientific journals on pharmacovigilance and pharmacoepidemiology and is a member of the editorial board of the journals of Pharmacoepidemiology and Drug Safety. Saad Shakir has led, co-ordinated and participated in many postgraduate educational and training programmes. He supervises postgraduate students for higher degrees and has been involved with a number of international initiatives to promote and develop pharmacovigilance and pharmacoepidemiology.

Pharmacovigilance risk management and risk minimisation and its effectiveness

Kieran O’Donnell has over 15 years of PV and since 2006 has been leading European and Global PV operations, gaining broad experience in PV QMS; Benefit-risk management; Signal Detection & Management; PSURs & DSURs; RSI development; ICSR and SUSAR submission; Inspection (MHRA GCP & PV and FDA PV inspections; ISO 9001:2000; and responsible roles such as the RP for EudraVigilance and Deputy QPPV for Pharmacovigilance. In addition to his PgC Pharmacovigilance, he has been a member of the RQA PV Committee since 2008 and is a Fellow of PIPA. He joined TMC in June 2014.

Pharmacovigilance, EudraVigilance, Signal Detection, Benefit-risk management

1980 - 1994 Qualified University of London, Guy\\\\\\\'s Hospital Medical School followed by hospital medicine and clinical research: general medicine, 6 years in renal medicine, principal investigator in London, Birmingham, and Manchester attached to Renal Unit Royal Infirmary 1994 -1999 Senior Medical Assessor UK Medicines Control Agency – Senior Medical Assessor in Pharmacovigilance Assessment Group. 1999 - 2005 Senior Medical Director in a global CRO – Parexel Scientific and Medical Services – with responsibilities in pharmacovigilance and clinical trials. 2005 - 2007 Deputy Qualified Person for pharmacovigilance for Janssen Cilag Since July 2007, Dr Edwards has been a Principal Consultant in Pharmacovigilance and Drug Safety with NDA Regulatory Science Ltd based in Leatherhead, Surrey, UK. In addition, he chairs the QA panel overseeing the training of UK pharmaceutical physicians on behalf of the UK Faculty of Pharmaceutical Medicine and he is Director of ISoP Secretariat Ltd, is on the ISoP Executive Committee and is Treasurer as of November 2012. He is also Vice President in the Alliance Clinical Research Excellence and Safety (ACRES). He is co-chair of PharmaHUF in the UK & Ireland.

hospital medicine and clinical research: general medicine

Marco Manfredi MD, pediatrician and gastroenterologist, is now adjunct professor at Parma University. He carried out his education at Parma University where completed his PhD in Pediatric Gastroenterology in 2004. Currently he is working as Assistant Manager in Pediatric Gastroenterology at “Pietro Barilla” Children's Hospital in Parma, Italy. His main fields of interests are Helicobacter pylori infection, coeliac disease, gastrointestinal infectious diseases, functional gastrointestinal diseases, and Probiotics. Dr Manfredi published more than 75 papers, included chapters of textbooks. He is editor of three textbooks on “Helicobacter pylori infection”, “Gastrointestinal Endoscopy in Children” and on “Probiotics in Children” published by Nova Science Publishers, New York, USA. He is serving as an editorial board member of several reputed journal like “Clinical Microbiology: open access” and “Frontiers in Pediatric Gastroenterology and Hepatology” and expert Reviewer for journals like BMC Gastroenterology, Saudi Journal of Gastroenterology, BMC Case Reports. He is a member of Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition.

Gastroenterology, Hepatology and Nutrition

Dr Mahmud Kajbaf holds a Ph.D. from the University of London, King’s College, Biopharmacy department in the area of drug metabolism and MSc from Aston University, Birmingham. Dr Kajbaf is currently Senior Scientist at Aptuit and more than 23 years of industrial experience in drug discovery and development in various therapeutic areas especially in CNS field, with a particular focus on In vitro assay development and use of mass spectrometry in drug metabolism. He is serving as an editorial member of several reputed journals and also as expert reviewers for several Journals. He has authored 32 research articles in in vitro and in vivo drug metabolism and mass spectrometry.

In vitro Drug metabolism, In Vitro assay development , Mass spectrometry in drug metabolism.

Presently working she is a Professor, habilitated doctor, chemist, Chemistry & Biochemistry Discipline, Banat’s University of Agricultural Sciences and Veterinary Medicine “King Michael I of Romania” from Timisoara,300645, Calea Aradului 119, Timis, Romania, Teaching chemistry and biochemistry plant (specific disciplines). She Pursued Postdoctoral Studies on"Formulation and evaluation of dermato–cosmetic products" in the field of dermato-cosmetic sciences, chemical quality and toxicity of cosmetics, and galenics, formulation and efficacy of dermatologic or cosmetic, from "Victor Babes" University of Medicine and Pharmacy of Timisoara

Chemistry and Analytical Biochemistry; Research on natural compounds or active principles of plants; Develop approaches for the chemical characterization of medicinal plants and plant mixtures using different methods.Research Interests: Chemistry and Analytical Biochemistry; Research on natural compounds or active principles of plants; Develop approaches for the chemical characterization of medicinal plants and plant mixtures using different methods.

Dr. Damatarca has over 17 years of experience in the biopharmaceutical industry, across all stages of development and product commercialization. In her current position as Vice President of Medical Affairs and Pharmacovigilance at Agility Clinical, Dr. Damatarca provides oversight for all medical affairs and drug safety activities for Agility Clinical, which focuses on rare diseases.Before joining Agility Clinical, Dr. Damatarca was Vice President and Head of Drug Safety and Pharmacovigilance at Clovis Oncology, where she provided oversight for all safety aspects of the clinical development program for Clovis oncology molecules.Before that, Dr. Damatarca served as Executive Director and Head of Safety at Avanir Pharmaceuticals, where her responsibilities included oversight of clinical trials and postmarketing safety, pharmacovigilance, medical review, signal detection, aggregate reporting, and risk management. Previous functions included senior roles in Pharmacovigilance as Therapeutic Area Head for the Oncology Signaling Franchise at Genentech-Roche and before that, as Global Safety Officer and Global Safety Forum Chair at Amgen for various products in Oncology, Oncology–Hematology, and Inflammation-Internal Medicine. While at Amgen, she also served as the Chair of the Global Safety Forum, an internal advisory board for safety issues. Prior to Amgen, Dr. Damatarca worked in drug safety at several pharmaceutical companies. At Amylin Pharmaceuticals, she worked on products within the company’s product portfolio in the diabetes and metabolic disorders pipeline, most notably on two new molecular entities in diabetes. At Ligand Pharmaceuticals, she worked on several drugs in Oncology and Pain, and served as safety officer for various international clinical trials. During her tenure in drug safety and pharmacovigilance at various pharmaceutical companies, Dr. Damatarca participated in several Drug Advisory Committees and served on the teams who developed REMS - RiskMAP – risk management programs for various products, some of these having played a key role in optimizing the benefit-risk profile of the products.

Drug Safety and Pharmacovigilance

Dr Subodh Bhardwaj is a qualified Physician and Clinical pharmacologist with 3 decades of experience in the pharmaceutical Industry leading research and development of Vaccines and Biopharmaceuticals . Qualified MBBS from Medical College Jammu, India in 1981 and worked in Internal Medicine for 7 years, before qualifying MD Pharmacology from the prestigious AMU in India in 1990. He was associated with research on Hypertension, diabetes and trace elements till 1993.He joined as Medical Director of Serum Institute of India in 1993- the largest exporter of Vaccines globally and conducted research on Bacterial & Viral Vaccines- licensing DTPwHB, HB, Hib, DTPwHB Hib, MMR, MR, R, HDC Rabies Vaccines, Infertility drugs, Somatostatin, Somatropin & Onco BCG for Superficial Bladder Cancer as adjunctive therapy. His experience blends special skills in Pharmacovigilance of drugs & pharmaceuticals across broad therapeutic groups including Monoclonals for rabies. He has managed Pharmacovigilance, as Director Medical, Regulatory & Public Policy of Sanofi Pasteur India from 2008-2011 when notable products licensed were- Acellular Pentavalent IPV containing Vaccines, Pandemic and Seasonal Influenza Vaccines, Boosters, Yellow fever vaccine, Meningococcal vaccines among others. Well versed with Marketing and distribution of anticancers, Biologicals in Uganda as Director Medical Affairs Surgipharm Uganda & Rwanda from 2013-2015. Leading Clinical research & Pharmacovigilance in Vaccines& Pharma- he has organized large sample size trials from Preclinical to licensure and Post Marketing Surveillance in India and abroad. He is Member of BRAPP, European Society of Pharmacovigilance, with 60 National & International publications in reputed journals. He currently works as Biopharmaceutical Consultant & Vice President Arable Corporation besides consulting for International organizations on topics of Public health importance.

Pharmacovigilance, Clinical research, Influenza Vaccines, Viral Vaccines, Meningococcal vaccines, Yellow fever vaccine

Dr J Vijay Venkatraman is a Diabetologist, Drug Safety Physician and Entrepreneur, with an overall experience of 14 years, of which the last 8 years have been in the Pharmacovigilance industry. He holds a MBA degree in Services Management and has been awarded the Fellowship of the Pharmaceutical Information & Pharmacovigilance Association, United Kingdom. Dr Vijay is the Chair of the Pharmacovigilance Council of the Indian Society for Clinical Research, for 2015-17. He is an Affiliate Member of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom. Dr Vijay founded Oviya MedSafe, a global Pharmacovigilance Consulting & Drug Safety Services company incorporated in Coimbatore, India in 2012 and London, UK in 2014, which has been catering to the international as well as the Indian pharmaceutical industry ever since its inception. Dr Vijay is an invited speaker in national and international conferences on Drug Safety as well as Diabetology. He has published in many national & international journals and magazines. He is actively involved in promoting pharmacovigilance awareness among doctors. Dr Vijay has been associated with various institutes as a Pharmacovigilance Trainer. He is also a practising Diabetologist at Diab-at-ease Clinik, KTVR Group Hospital, Coimbatore.

Diabetologist and Drug Safety

He has completed his education Mysore Medical College, India. He pursued his Fellowship , Neonatal-Perinatal Medicine at Baylor College of Medicine and post graduation in Pediatrics at Newark Beth Israel Medical Center. He is a fellow member of American Academy of Pediatrics (Perinatal Pediatrics). He also had membership in Southern Society for Pediatric Research and Texas Pediatric Society.

Neonatal-Perinatal Medicine, Pediatrics, Role of aryl hydrocarbon receptor in hyperoxic lung injury in newborn mice and human neonatal lung derived cells.

Mohamed Eddouks is Professor at Moulay Ismail University, Faculty of Sciences and Techniques Errachidia, Morocco. He is a researcher in Physiology and Pharmacology with a Master Degree in Metabolic and Molecular Endocrinology from University of Paris vi, a specialized certificate in Endocrine Pharmacology from University of Paris vii and PhD degrees in Physiology and Pharmacology from University of Liege, Belgium and Sidi Mohammed Ben Abdellah University, Fez, Morocco. After his post-doctoral fellowship at Department of Physiology, Faculty of Medicine of Montreal, Canada, he is working for the last 13 years on medicinal plants. His work on antidiabetic and antihypertensive plants is well recognized globally. His research focuses on ethnobiological as well as pharmacological issues in the use of Moroccan medicinal plants for the treatment of diabetes mellitus, obesity and hypertension. His contribution to this field includes three international books and more than 80 peer-reviewed articles and book chapters of international repute. He is Guest Editor of American Journal of Pharmacology and Toxicology, Lead Guest Editor of an annual special issue published by Evidence-Based and Complementary Alternative Medicine, Regional Editor of the Following journals: American Journal of Food Technology, Journal of Applied Sciences, Trends in Applied Sciences Research and Singapore Journal of Scientific research, Member of Editorial Board of several international journals. He has been honored with the first Prize of Scientific Research in 2008 by the Moroccan Association of Research and Development. He has been the Dean of Polydisciplinary Faculty of Errachidia from 2008 to 2012.

Pharmacology, Ethnopharmacology, Phytotherapy, Pharmacognosy, Phytochemistry, Toxicology, Diabetes, Hypertension, Obesity and Medicinal Plants.